JP2020502056A - 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 - Google Patents

糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 Download PDF

Info

Publication number
JP2020502056A
JP2020502056A JP2019524445A JP2019524445A JP2020502056A JP 2020502056 A JP2020502056 A JP 2020502056A JP 2019524445 A JP2019524445 A JP 2019524445A JP 2019524445 A JP2019524445 A JP 2019524445A JP 2020502056 A JP2020502056 A JP 2020502056A
Authority
JP
Japan
Prior art keywords
formulation
polypeptide
seq
rps2
img
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502056A5 (enExample
Inventor
タイ、ゴック
ポレット、ジョナサン
Original Assignee
イマジン ファーマ
イマジン ファーマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマジン ファーマ, イマジン ファーマ filed Critical イマジン ファーマ
Publication of JP2020502056A publication Critical patent/JP2020502056A/ja
Publication of JP2020502056A5 publication Critical patent/JP2020502056A5/ja
Priority to JP2023016485A priority Critical patent/JP7711967B2/ja
Priority to JP2025113059A priority patent/JP2025163025A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019524445A 2016-11-13 2017-11-13 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 Pending JP2020502056A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023016485A JP7711967B2 (ja) 2016-11-13 2023-02-07 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
JP2025113059A JP2025163025A (ja) 2016-11-13 2025-07-03 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421332P 2016-11-13 2016-11-13
US62/421,332 2016-11-13
PCT/US2017/061343 WO2018089909A1 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016485A Division JP7711967B2 (ja) 2016-11-13 2023-02-07 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2020502056A true JP2020502056A (ja) 2020-01-23
JP2020502056A5 JP2020502056A5 (enExample) 2021-01-07

Family

ID=62107069

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019524445A Pending JP2020502056A (ja) 2016-11-13 2017-11-13 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
JP2023016485A Active JP7711967B2 (ja) 2016-11-13 2023-02-07 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
JP2025113059A Pending JP2025163025A (ja) 2016-11-13 2025-07-03 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023016485A Active JP7711967B2 (ja) 2016-11-13 2023-02-07 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
JP2025113059A Pending JP2025163025A (ja) 2016-11-13 2025-07-03 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法

Country Status (9)

Country Link
US (2) US10548941B2 (enExample)
EP (1) EP3538124A4 (enExample)
JP (3) JP2020502056A (enExample)
KR (1) KR102497242B1 (enExample)
CN (1) CN110087666B (enExample)
AU (2) AU2017357052B2 (enExample)
BR (1) BR112019009511A2 (enExample)
MX (1) MX2019005466A (enExample)
WO (1) WO2018089909A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023071670A (ja) * 2016-11-13 2023-05-23 イマジン ファーマ、エルエルシー 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510157A (ja) * 2018-01-09 2021-04-15 イマジン ファーマ、エルエルシー 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
WO2020005721A1 (en) * 2018-06-25 2020-01-02 Imagine Pharma, Llc Compositions and methods for propagating insulin-producing islet cells and therapeutic uses thereof
CN110974943A (zh) * 2019-12-09 2020-04-10 广东药科大学 一种口服胰岛素药物制剂及其制备方法
JP2023552515A (ja) * 2020-12-08 2023-12-18 イマジン ファーマ、エルエルシー 創傷を治療するための組成物および方法
WO2023049079A2 (en) * 2021-09-22 2023-03-30 Imagine Pharma Llc Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
CA3235948A1 (en) * 2021-12-11 2023-06-15 Ngoc THAI Compositions and methods for oral administration
WO2025207834A1 (en) * 2024-03-28 2025-10-02 Imagine Pharma Llc Dietary supplements, compositions, and uses thereof for increasing telomerase activity and extending telomere length

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10337187A (ja) * 1997-04-09 1998-12-22 Kao Corp 新規ペクチン酸リアーゼ
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2004537274A (ja) * 2001-02-15 2004-12-16 コンドロジェネシス ピーティーワイ リミテッド 軟骨形成におけるマトリックス遺伝子発現
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
US20040014040A1 (en) * 2001-07-10 2004-01-22 Donna Mendrick Cardiotoxin molecular toxicology modeling
EP2275120A3 (en) * 2002-04-02 2011-06-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
AU2004251654A1 (en) * 2003-06-02 2005-01-06 Icoria, Inc. Use of genes differentially expressed during aging of liver for treatment and diagnosis
US20090048199A1 (en) * 2007-03-09 2009-02-19 Hiberna Corporation Hibernation-Related Genes and Proteins, Activators and Inhibitors Thereof and Methods of Use
US9221886B2 (en) * 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2012054739A2 (en) * 2010-10-21 2012-04-26 New York University Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
CA2817851A1 (en) * 2010-11-12 2012-05-18 The Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
ES3039965T3 (en) 2011-03-01 2025-10-28 NuCana plc Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
EP3048904A2 (en) * 2013-09-25 2016-08-03 Pronutria Biosciences, Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
MD20170035A2 (ro) * 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
CN110087666B (zh) 2016-11-13 2024-04-30 想象制药公司 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
JP2021510157A (ja) * 2018-01-09 2021-04-15 イマジン ファーマ、エルエルシー 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10337187A (ja) * 1997-04-09 1998-12-22 Kao Corp 新規ペクチン酸リアーゼ
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2004537274A (ja) * 2001-02-15 2004-12-16 コンドロジェネシス ピーティーワイ リミテッド 軟骨形成におけるマトリックス遺伝子発現
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023071670A (ja) * 2016-11-13 2023-05-23 イマジン ファーマ、エルエルシー 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
JP7711967B2 (ja) 2016-11-13 2025-07-23 イマジン ファーマ、エルエルシー 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法

Also Published As

Publication number Publication date
CN110087666A (zh) 2019-08-02
JP2023071670A (ja) 2023-05-23
EP3538124A4 (en) 2020-07-22
AU2017357052B2 (en) 2022-03-24
EP3538124A1 (en) 2019-09-18
CN110087666B (zh) 2024-04-30
US20180133280A1 (en) 2018-05-17
AU2017357052A1 (en) 2019-05-02
KR20190084070A (ko) 2019-07-15
JP2025163025A (ja) 2025-10-28
KR102497242B1 (ko) 2023-02-09
JP7711967B2 (ja) 2025-07-23
AU2022203741A1 (en) 2022-06-23
US10548941B2 (en) 2020-02-04
US20200222499A1 (en) 2020-07-16
CA3041362A1 (en) 2018-05-17
AU2022203741B2 (en) 2024-02-15
BR112019009511A2 (pt) 2019-07-30
WO2018089909A1 (en) 2018-05-17
MX2019005466A (es) 2019-10-02
US10751384B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
JP7711967B2 (ja) 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法
JP5658619B2 (ja) 経口インスリン治療及びプロトコール
US8962554B2 (en) Oral insulin therapies and protocol
PT896538E (pt) Utilizacao de efectores da dipeptidilpeptidase iv que diminuem a sua actividade para baixar o teor em glucose no sangue em mamiferos
EP3268029B1 (en) Treatment of type 2 diabetes mellitus patients
CA2511530C (en) Night-time oral insulin therapy
CN112279920A (zh) FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
JP6716187B2 (ja) アディポネクチン受容体に対する作用薬ペプチド
US20080194483A1 (en) GLP-1 (9-36) methods and compositions
US11612637B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US20230263856A1 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
CA3041362C (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
JP2016526533A (ja) アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
WO2010055711A1 (ja) Ｓｉｒｓ患者を救命するためのペプチド組成物
JP2006519881A (ja) 経口インスリン治療及びプロトコール
CN113509544B (zh) 一种具有降血糖作用的药物组合物
ZA200505426B (en) Night-time oral insulin therapy
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
KR20220110506A (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제를 사용하는 조합 치료법
TW202140061A (zh) 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
TW202045532A (zh) 重組蛋白用於治療代謝疾病
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
EP2421547A1 (en) Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011